These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 31107628)

  • 1. Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer.
    Hu J; Aprikian AG; Vanhuyse M; Dragomir A
    J Oncol Pract; 2019 Jun; 15(6):e510-e519. PubMed ID: 31107628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
    Afshar M; Evison F; James ND; Patel P
    Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
    Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
    Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based study on use of chemotherapy in men with castration resistant prostate cancer.
    Lissbrant IF; Garmo H; Widmark A; Stattin P
    Acta Oncol; 2013 Nov; 52(8):1593-601. PubMed ID: 23427879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.
    Westgeest HM; Kuppen MCP; van den Eertwegh FAJM; van Oort IM; Coenen JLLM; van Moorselaar JRJA; Aben KKH; Bergman AM; Huinink DTB; van den Bosch J; Hendriks MP; Lampe MI; Lavalaye J; Mehra N; Smilde TJ; Somford RDM; Tick L; Weijl NI; van de Wouw YAJ; Gerritsen WR; Groot CAU
    J Palliat Med; 2021 Dec; 24(12):1789-1797. PubMed ID: 34415798
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
    Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
    Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.
    McKay RR; Werner L; Fiorillo M; Nakabayashi M; Kantoff PW; Taplin ME
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):398-405. PubMed ID: 27502737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
    Tanaka M; Kimura T; Iwamura Y; Enei Y; Iwamoto Y; Imai Y; Inaba Y; Matsukawa A; Onuma H; Ito K; Mori K; Sasaki H; Miki J; Furuta A; Miki K; Egawa S
    Prostate; 2019 Oct; 79(14):1604-1610. PubMed ID: 31376184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database.
    Mohamad Al-Ali B; Kramer G; Madersbacher S; Berger I
    Wien Klin Wochenschr; 2017 Jun; 129(11-12):380-384. PubMed ID: 27596230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
    Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
    Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
    Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
    Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.